Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Galassi C, Klapp V, Formenti SC, Demaria S, Galluzzi L. Immunologically relevant effects of radiation therapy on the tumor microenvironment. Essays Biochem. 2023.

Halabi KC, Ross B, Acker KP, Cannon J-, Messina M, Mangino D, et al. Successful diagnostic stewardship for Clostridioides difficile testing in pediatrics. Infect Control Hosp Epidemiol. 2023;44(2):186-190.

Lin LH, Tran I, Yang Y, Shen G, Miah P, Cotzia P, et al. DNA Methylation Identifies Epigenetic Subtypes of Triple-Negative Breast Cancers With Distinct Clinicopathologic and Molecular Features. Mod Pathol. 2023;36(11):100306.

Xu Z, Yang HS, Liu L, Meng L, Lu Y, Han L, et al. Elevated levels of renal function tests conferred increased risks of developing various pregnancy complications and adverse perinatal outcomes: insights from a population-based cohort study. Clin Chem Lab Med. 2023;61(10):1760-1769.

Oh W-, Yang Y-, Xie J, Ma H, Kim J-, Park K-, et al. WNT-modulating gene silencers as a gene therapy for osteoporosis, bone fracture, and critical-sized bone defects. Mol Ther. 2023;31(2):435-453.

Liu D, Cheng Y, Zhou H, Wang L, Fiel RH, Gruenstein Y, et al. Early Introduction and Community Transmission of SARS-CoV-2 Omicron Variant, New York, New York, USA. Emerg Infect Dis. 2023;29(2):371-380.

Barone P, Patel S. Myelodysplastic syndrome: Approach to diagnosis in the era of personalized medicine. Semin Diagn Pathol. 2023;40(3):172-181.

Schreidah CM, Fahmy LM, Lapolla BA, Kwinta BD, Magro CM, Geskin LJ. Clinical Remission of Primary Cutaneous Marginal Zone B-Cell Lymphoma in a Patient With Crohn's Disease After Helicobacter pylori Quadruple Therapy and Vedolizumab. Am J Dermatopathol. 2023;45(8):572-576.

Geyer JT, Kluk MJ. Current Landscape of Ancillary Diagnostic Testing in Chronic Lymphocytic Leukemia. Surg Pathol Clin. 2023;16(2):411-421.

Ruan J, Moskowitz A, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, et al. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023;141(18):2194-2205.